Today: 21 May 2026
Ondas Holdings stock today: ONDS jumps on $10 million orders as new 2x ETF debuts
1 January 2026
2 mins read

Ondas Holdings stock today: ONDS jumps on $10 million orders as new 2x ETF debuts

NEW YORK, January 1, 2026, 07:26 ET — Market closed

  • Ondas shares last closed up 8.6% at $9.76, after touching $10.53 intraday on heavy volume.
  • The company said it received about $10 million in new purchase orders for its autonomous systems portfolio.
  • An SEC filing showed CEO Eric Brock sold shares to cover tax obligations tied to a recent exchange agreement.

Ondas Holdings Inc shares ended the year’s final U.S. session up 8.6% at $9.76, after the company announced about $10 million in new autonomous systems orders. The stock hit an intraday high of $10.53 and traded about 156.2 million shares, according to data compiled by StockAnalysis.

The move matters because Ondas has become a high-beta, event-driven name, where fresh order flow can quickly reset expectations for near-term revenue. For smaller defense-tech suppliers, investors tend to treat purchase orders — written commitments to buy products or services — as a harder signal than pipeline commentary.

It also lands as new trading vehicles widen the audience for single-stock volatility. With U.S. markets shut Thursday for the New Year’s Day holiday, positioning for Friday’s reopen is likely to focus on whether Wednesday’s surge holds when normal liquidity returns.

Ondas said the new purchase orders span counter-UAS systems — technology that detects and disrupts drones — alongside integrated autonomous drone systems and robotic ground platforms for government and critical infrastructure customers. “2025 has been a defining year for Ondas, with record results, expanding customer programs, and clear validation of our multi-domain autonomy strategy,” Chairman and CEO Eric Brock said. The company also pointed to $16.4 million in fourth-quarter orders tied to counter-UAS deployments at large European airports and said an initial purchase order for a border-protection program is expected in January 2026. Ondas Holdings Inc.

A separate catalyst is the debut of a leveraged single-stock exchange-traded fund tied to Ondas. The Defiance Daily Target 2X Long ONDS ETF, ticker ONDL, was listed on Dec. 30 and seeks to deliver 200% of Ondas’ daily share-price move — a structure that resets each day and can magnify swings in both directions.

Ondas operates through an autonomous systems unit and a private wireless business, targeting defense, security and mission-critical industrial customers. The counter-drone and military robotics market also includes companies such as AeroVironment and Kratos Defense & Security Solutions, where contract announcements and procurement timelines can drive sharp, sentiment-led moves.

An SEC Form 4 filing showed Brock sold 475,000 shares on Dec. 31 at a weighted average price of $9.7081. The filing said the sale was made to cover tax obligations related to an exchange agreement involving Ondas Autonomous Systems, and it listed Brock as holding 1,461,255 shares after the transaction.

Ondas’ investor relations filings page also showed additional Form 144 submissions dated Dec. 31. A Form 144 is a notice of a proposed sale of restricted or control securities, and it can put short-term focus on insider supply — even when it does not guarantee sales will occur.

U.S. stock markets are closed Thursday for New Year’s Day, and trading is set to resume Friday.

Before the next session, traders will be watching whether ONDS can hold above the mid-$9 area after the spike in volume, and whether it retests Wednesday’s $10-plus zone. MarketBeat data showed a 52-week range of $0.57 to $11.70, with the stock’s 50-day moving average near $7.62 and its 200-day moving average near $5.73.

Macro data could also affect risk appetite for smaller, fast-moving defense-tech names early in the new year. ISM said its next Manufacturing PMI report is due at 10:00 a.m. ET on Monday, Jan. 5, while the Labor Department’s December employment report is scheduled for Friday, Jan. 9.

Stock Market Today

  • Borr Drilling Moves to Main Euronext Oslo Børs Market
    May 20, 2026, 8:34 PM EDT. Borr Drilling (BORR) has received approval to transfer its share listing from Euronext Growth Oslo to the main market of Euronext Oslo Børs. This upgrade reflects Borr Drilling's progress and adherence to higher regulatory and reporting standards required by the main market. The move aims to increase the company's visibility and appeal to a broader base of investors, supporting liquidity and trading activity. This transition marks a significant step for Borr Drilling in aligning with more established Nordic market practices.

Latest articles

SPAC ETF Up as SpaceX Heads for SPCX Ticker

SPAC ETF Up as SpaceX Heads for SPCX Ticker

21 May 2026
The SPAC and New Issue ETF, now trading as SPCK, closed up 0.64% at $22.09 on Wednesday after SpaceX filed for a $75 billion IPO under the fund’s old ticker. The fund reported $7.14 million in net assets and 41 holdings as of May 19. New listings included a $75 million IPO from Research Alliance III and filings from FutureCorp Space Acquisition 1 and JAB Acquisition I. The SEC proposed easing share issuance rules for public companies.
EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

EnerSys Stock Flips After Earnings as Guidance Tops Trader Hopes

21 May 2026
EnerSys shares rose in after-hours trading after the company posted fourth-quarter adjusted earnings of $3.19 per share on $988 million in revenue, both above analyst estimates. The stock closed regular hours down 1.3% at $214.56, then quoted up 5.8% to $227. First-quarter profit guidance also topped forecasts. Management cited strong data center and defense demand, but noted continued weakness in motive-power and transportation.
Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

Silexion Soars After Cancer Study, Liquidity and Nasdaq Issues Linger for SLXN

21 May 2026
Silexion Therapeutics shares surged 97% to $0.5298 on Wednesday with over 325 million shares traded, then fell 9.5% after hours. The move followed news that Israel approved a Phase 2/3 trial of its lead pancreatic cancer drug, SIL204. Silexion reported a Q1 net loss of $2.7 million and $2.4 million in cash. The company plans a 1-for-10 reverse share split by early June.
Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD
Previous Story

Outlook Therapeutics stock drops after FDA issues another Lytenava CRL for wet AMD

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next
Next Story

Apple stock slips into 2026 as year-end tech pullback bites; AAPL earnings next

Go toTop